Class of therapeutic protein based molecules
The present invention provides new compositions and methods for preventing and treating pathogen infection. In particular, the present invention provides compounds having an anchoring domain that anchors the compound to the surface of a target cell, and a therapeutic domain that can act extracellularly to prevent infection of a target cell by a pathogen, such as a virus. The present invention also comprises therapeutic compositions having sialidase activity, including protein-based compounds having sialidase catalytic domains. Compounds of the invention can be used for treating or preventing pathogen infection, and for treating and reducing allergic and inflammatory responses. The invention also provides compositions and methods for enhancing transduction of target cells by recombinant viruses. Such compositions and methods can be used in gene therapy.
1. A method of treating or preventing infection by respiratory syncytial virus, the method comprising applying a therapeutically effective amount of a pharmaceutical formulation comprising:
a polypeptide comprising an amino acid sequence that begins at any of the amino acids from amino acid 270 to amino acid 290 of SEQ ID NO:12 and ends at any of the amino acids from amino acid 665 to amino acid 901 of SEQ ID NO:12, wherein the isolated polypeptide does not comprise the sequence extending from amino acid 1 to amino acid 269 of SEQ ID NO:12 and wherein the isolated polypeptide has sialidase activity
to epithelial cells of a subject.
2. The method of claim 1 wherein the polypeptide comprises an amino acid sequence that begins at any of the amino acids from amino acid amino acids 270 to 290 of SEQ ID NO:12 and ends at any of amino acid residues 665 to 681 of SEQ ID NO:12.
3. The method of claim 2 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:16.
4. The method of claim 1 wherein the polypeptide comprises an amino acid sequence that begins at amino acid 274 of SEQ ID NO:12 and ends at amino acid 681 of SEQ ID NO:12.
5. The method of claim 1 wherein the polypeptide comprises an amino acid sequence that begins at amino acid 290 of SEQ ID NO:12 and ends at amino acid 666 of SEQ ID NO:12.
6. The method of claim 1 wherein the polypeptide comprises an amino acid sequence that begins at amino acid 290 of SEQ ID NO:12 and ends at amino acid 681 of SEQ ID NO:12.
7. The method of claim 1 wherein the polypeptide further comprises the amino acid sequence of SEQ ID NO:7.
8. The method of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 23.
9. The method of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 25.
10. The method of claim 1 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 27.
11. The method of claim 1 wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 23.
12. The method of claim 1 wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 25.
13. The method of claim 1 wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 27.
14. The method of claim 1 wherein the subject is infected by respiratory syncytial virus.
15. The method of claim 1 , wherein the step of applying the pharmaceutical composition comprises inhaling the pharmaceutical composition.